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Pancreatic adenocarcinoma is an aggressive disease with an extremely high mortality 
rate. New therapies are needed to treat this deadly disease. Gold nanoparticles (GNP) are 
attractive vehicles for cancer therapeutics. The chemistry of gold allows for easy attachment of 
therapies. In addition GNP can also access tumors through the leaky vasculature. Boron Neutron 
Capture Therapy (BNCT) involves localizing non-toxic and non-radioactive Boron-10 to tumor 
cells. When a boron-10 atom is hit with low thermal energy neutrons it decays into destructive 
high-energy lithium ions and α-particles. By loading boron onto GNP, the therapeutic delivery to 
tumors can potentially be increased. The success of BNCT also relies on targeting the boron 
specifically to the tumor in order to localize damage to the tumor. Through attaching an antibody 
that recognizes a cell surface protein on pancreatic adenocarcinoma cells to the GNP the boron 
can be directed to the tumor. Here glycoprotein A33 is used as the target. Pancreatic 
adenocarcinoma cell line BxPC3 does not express A33, while another pancreatic cancer cell line 
CAPAN2 does. This model allows for the selectivity of boron loaded monoclonal antibody 
conjugated gold nanoparticles to be evaluated. In order to expose the cells to low thermal energy 
neutrons they must be transported to MIT Nuclear Reactor Lab, which involves cell culture in 
CO2 independent conditions. Culture of cell in CO2 independent conditions caused no significant 
morphological changes and importantly A33 expression did not change significantly in BxPC3 
and CAPAN2 cell lines. An initial irradiation experiment was performed with monoclonal 
conjugated boron loaded gold nanoparticles constructs that provides a platform for additional 
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Challenges of Treating Pancreatic Cancer 
Pancreatic adenocarcinoma represents one of the largest challenges in cancer treatment 
today.  In 2014 there will be an estimated 39,560 deaths due to pancreatic cancer, making 
pancreatic cancer the fourth most lethal form of cancer (Siegel et al., 2014). The 5 year survival 
rate of pancreatic cancer is less than 5% (Siegel et al., 2014). 
Due to a lack of clinical symptoms, pancreatic cancer often goes undiagnosed until the 
cancer reaches advanced and often metastatic stages (Stathis and Moore, 2010). Upon diagnosis 
less than 20% of patients present with operable tumors (Vincent et al., 2011). Even with surgical 
resection most pancreatic cancer patients relapse due to the inaccessibility of the tumor in the 
pancreas (Neoptolemos, 2011). The most commonly used treatment for advanced pancreatic 
cancer is the nucleotide analog gemcitabine (Feig et al., 2012). However gemcitabine only 
modestly increased survival time from the former chemotherapeutic drug 5-Fluorouracil. 
However, it showed a significant improvement in the quality of life of the patients (Burris et al., 
1997). Recent clinical trials have used gemcitabine combined with erlotinib, an epithelial growth 
receptor inhibitor. This combination therapy does come with some increase in toxicity and 
symptoms (Moore et al., 2007). However, it showed a slight but statistically significant increase 
in patient survival relative to treatment with just gemcitabine (Moore et al., 2007). In spite of 
minor advances using existing therapies, there is still an unmet need for novel therapies to 
combat advanced pancreatic cancer. 
There are multiple factors that contribute to the chemotherapy resistance in pancreatic 
cancers. Pancreatic cancer metastases are highly genetically heterogeneous, which provides a 
means for selection for cells resistant to chemotherapy (Campbell et al., 2010; Yachida et al., 
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2010). Pancreatic cancer stem cells have also been recently been implicated in tumor growth and 
metastasis (Lee et al., 2008). Traditional chemotherapies are often inefficient at killing cancer 
stem cells, which provides a mechanism for resistance. New therapies are needed to treat this 
invasive disease in addition to traditional chemotherapies.  
Boron Neutron Capture Therapy 
Boron Neutron Capture Therapy (BNCT) seems to be a promising alternative to the 
current pancreatic cancer therapies. BNCT involves targeting a non-toxic, non-radioactive 
isotope of boron, boron-10, to tumor cells. When a boron-10 atom is hit with low thermal energy 
neutrons it decays into high-energy lithium ions and α-particles  (Barth et al., 1990)  (Fig 1). The 
high molecular weight of the species gives them a limited path length of about the radius of a 
cell. Localizing boron-10 within tumor cells limits cellular damage to within the tumor.  The α-
particles produced are not compromised by hypoxic environments, such as those found in the 
core of larger tumors (Barth et al., 1990). In contrast to most chemotherapies and radiation 
therapy, BNCT kills indiscriminately between rapidly proliferating cells and quiescent cells 
(Barth et al., 1990). This lack of specificity for proliferating cells indicates that BNCT could kill 
the non-neoplastic cells in the stroma that can influence tumor growth. Recently, BNCT has been 
shown to arrest and induce apoptosis in glioma stem cells (Sun et al., 2013). These advantages 
make BNCT an appealing alternative to traditional chemotherapies for treating pancreatic cancer.  
Originally BNCT was developed as a treatment for glioblastoma multiforme (Hawthorne, 
1993),  partially because boron naturally localizes to brain tumors (Barth et al., 2005).   The 
initial clinical trials of BNCT produced insignificant results (Barth et al., 1990). Later analysis 
revealed three key problems with this approach (Barth et al., 2005). One of the limitations of 
BNCT has been the difficulty of getting a high enough concentration of Boron-10 into the tumor 
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to inflict extensive damage. Secondly, there was enough residual 10B present in the blood at the 
time of irradiation to cause damage to the surrounding tissue. Finally low thermal energy 
neutrons did not have great enough penetrance to allow for sufficient radiation exposure for 
many tumors. Over the years various low molecular weight boron delivery agents including, 
BPA and BSH (Fig 2), have been used in BNCT clinical trials (Barth et al., 2005). More recent 
pre-clinical BNCT studies have placed an emphasis on using modern nanotechnology to 
facilitate boron delivery in order to overcome the challenges of BNCT, including a recent study 
that used liposomes to deliver 10B to xeonografts in mice (Kueffer et al., 2013). 
 
 
Figure 1: Schematic of the Mechanism of Boron Neutron Capture Therapy. When low 
thermal energy neutrons collide with boron-10 the collision produces destructive recoiling 
lithium ions and α particles. In order for BNCT to be effective Boron-10 is localized inside 
tumor cells, because the path-length of recoiling lithium ions and α particles is about the 
















GNPs are attractive vehicles for therapeutics due to their very low toxicity in biological 
systems, easy linker chemistry due to stable dative linkages with thiols and high surface to 
volume ratio, which enables therapeutic and targeting moieties to be attached to a single particle 
(Conde et al., 2012). In addition, GNP can also access tumors through the leaky vasculature, 
which makes them ideal carriers for cancer therapeutics. We believe loading boron-10 on gold 
nanoparticles (GNP) would increase the boron concentration that could be introduced into the 
system. 
 
Monoclonal Antibody Therapy 
Due to the natural localization of boron to brain tumors, BNCT was primarily used for 
glioblastomas and cranial melanomas (Barth et al. 2005). However through a targeted delivery 
system, this limitation on BNCT might be eliminated. One characteristic of over 50% of 
























al., 2000). Monoclonal antibodies targeted to A33 are rapidly endocytosed by cancer cells, which 
makes this protein an ideal target for therapeutic delivery (Mihaylova, 2006).  The pancreatic 
adenocarcinoma cell line, CAPAN2, robustly produces glycoprotein A33 while another 
pancreatic adenocarcinoma cell line, BxPC3, has no detectible levels of A33 protein expression. 
This provides a useful model system for investigating targeted delivery. 
 
Boron-Loaded Monoclonal-Antibody-Conjugated Gold Nanoparticles 
 In addition to the short penetrance of low thermal energy neutrons, there are two main 
issues with BNCT, insufficient boron load in the tumor to achieve maximal effect and the 
tendency of BSH and other boron compounds stay in the blood. We suggest a model where GNP 
particles are loaded with boron-10, to allow for high cellular cytotoxicity, and are conjugated to 
mAb in order to target the constructs specifically to pancreatic cancer cells overexpressing A33. 
The anti-A33 antibody (As33) is directionally conjugated to the gold with the variable region 
facing outward using a dithiol-PEG-hydrazine linker (Kumar et al., 2008). The hydrazine reacts 
with an oxidized glycosylation site on the Fc region of As33, while the dithiol enables an 
attachment to the gold (Kumar et al., 2008). The As33 antibodies remain stably attached to the 
GNP at about 15 antibodies per particle for approximately a month in solution before decreasing 
(Fig 4, Natarajan unpublished results). This indicates that the antibody conjugation will remain 
intact over the short time course of a cell based irradiation experiment.  
Since BSH has a thiol group (Fig 2), BSH was directly attached to the gold nanoparticles 
through a dative linkage. The particles were backfilled with polyethylene glycol (PEG), which is 
a flexible molecule and increases biocompatibility by increasing the hydrodynamic radius, 










Figure 4: As33 Antibody Loading and Stability on Gold Nanoparticles. As33 levels on gold 
nanoparticles were measured by ELISA each week for 8 weeks. The nanoparticle constructs 
(GNP-As33) were captured using protein A and assayed for antibody content with a goat anti-

































 This study aimed to evaluate the targeted delivery of monoclonal conjugated boron 
loaded gold nanoparticles to pancreatic cancer cells, CAPAN2 (A33+) and BxPC3 (A33-). In 
order to complete these experiments at the MIT nuclear reactor, the cells were conditioned to a 
CO2 independent conditions that did not drastically alter cell physiology, particularly A33 
expression. An initial irradiation experiment was performed with monoclonal conjugated boron 
loaded gold nanoparticles constructs, this experiment provides a platform for additional 






























Materials and Methods 
 
Cell lines and culture  
BxPC-3 and CAPAN2, human pancreatic adenocarcinoma cell lines, were purchased 
from American Type Culture Collection (ATCC). Both cell lines were carried in RPMI media 
(Sigma #R6504) supplemented with 0.2% sodium bicarbonate (Sigma #S8761), antibiotic 
solution (100 units/ml penicillin, 0.1 mg/ml streptomycin sulfate, 0.25 µg/ml amphotericin B; 
Sigma #A5955), and 10% fetal bovine serum (BioWest #S162H). The cells were passaged at 70-
80% confluency at ATCC recommended dilution ratios 1:4 and 1:6 CAPAN2 and BxPC3 
respectively.  
 
Conditioning Cells to an Unregulated CO2 Environment  
BxPC3 and CAPAN2 cell lines were directly adapted to CO2 Independent Media 
(GIBCO, Life Technologies # 18045) supplemented with 4 mM L-glutamine (GIBCO, Life 
Technologies #25030-081), 10% % fetal bovine serum (BioWest #S162H) and antibiotic 
solution (100 units/ml penicillin, 0.1 mg/ml streptomycin sulfate, 0.25 µg/ml amphotericin B; 
Sigma #A5955). The cells were seeded into CO2 Independent Media and placed a 37˚C incubator 
with 0% CO2.  According to the manufacturer’s instructions for the first passage, the cells were 
cultured in a closed flask while subsequent passages were cultured in an open flask. BxPC3 and 
CAPAN2 cell lines went through three passages in CO2 Independent Media before use in 





Viability Assay to Compare Normal Conditions and CO2 Independent Conditions  
BxPC3 and CAPAN2 cell lines were seeded in triplicate at 5,000 cells per well in two 
separate 96 well plates. One plate was kept at 37˚C in 5% CO2, while another plate was 
maintained at 37˚C in 0% CO2. Under 0% CO2, cells were either grown in RPMI or CO2 
Independent Media. The cells grown in CO2 Independent media had been conditioned in CO2 
Independent conditions for three passages (see above). Under 5% CO2, the cells were grown in 
complete RPMI (see above).  After 24 hours fresh media was added. As a positive control for 
cell death, the topoisomerase inhibitor etoposide (Sigma #E1383) was added to cells grown in 
normal conditions at a final concentration of 1 mM and incubated for 1 h. After 1 hour, the cell 
viability reagent WST-8 (Cell Counting Kit 8 CCK8; Dojindo #CK04) was added to all wells to 
reach a final concentration of 10%. In addition a blank (media and 10% WST-8) was added to 
each plate for both types of media.  Following a three-hour incubation the reactions were read at 
450 nm in a Molecular Devices M3 plate reader. Cell viability was determined as a percentage of 
the cells grown under normal conditions. Blank-corrected absorbance values of the treatment 
condition were divided by the blank-corrected absorbance values of the cells grow under normal 
conditions (RPMI, 5% CO2, 37˚C).  
 
Protein Extraction and Quantification 
 Cells were pelleted in PBS pH 7.4 and frozen “dry” at -80˚ C. The cells were resuspended 
in mammalian Protein Extraction Reagent (mPER, Thermo #78501) containing 1X HALT 
protease inhibitor cocktail (AEBSF 1mM, Aprotinin 800 nM, Bestatin 50 µM, E64 15 µM, 
Leupeptin 20µM, Pepstatin A 10 µM; Thermo Scientific #87786) in an approximate ratio of 1 
mL of mPER / 100 mg of pellet. The cell suspension was shaken at room temperature for 10 
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minutes. The supernatant lysate was carefully recovered after removal of cellular debris by 
centrifuging at 14,000 x g for 15 minutes.  
 The Pierce BCA Protein Assay Kit (Thermo #23235) was used according to 
manufacturer’s instructions to estimate total protein levels in the cell lysates. The BCA standard 
was diluted in a serial ½ dilution from a starting concentration of 2000 µg. The protein lysates 
were diluted 1:2 and 1:5. In duplicates the sample and protein standards were added in 1:8 ratio 
with the working reagent (25:24:1 Reagent A, Reagent B, Reagent C respectively) in a 96 well 
plate. After shaking to mix, the samples were incubated for 30 minutes at 37˚C.  The absorbance 
was measured at 562 nm in a Molecular Devices M3 plate reader. A blank-corrected BCA 
standard curve was created.  From the equation generated by the standard curve the 
concentration of the protein samples were calculated.  
 
Western Blot 
In order to denature proteins, the protein lysates were heated for 5 min at 90˚C in 1X 
Lane Marker Non-Reducing Sample Buffer (Thermo Scientific #39001).  Samples (10 µg of 
protein) and 7 uL of Pre Prestained SDS-PAGE Standards (BioRad #161-0309) were separated 
by SDS PAGE using a 10% polyacrylamide Precise Protein Gel (Thermo Scientific #25221) in 
TRIS-HEPES-SDS buffer (Thermo Scientific #28398) at 45V for 30 minutes and then 150V, 
until the loading dye was near the bottom of the gel.   
Upon removal, the gel was quickly washed in Nanopure water to remove excess buffer 
and detergent before gel and nitrocellulose membrane were equilibrated in 1 X Transfer Buffer 
(25 mM Tris Base, 192 mM glycine, and 20% methanol) for 20 minutes. The proteins were 
transferred to nitrocellulose membrane at 40V for 90 minutes in 1 X Transfer Buffer. After the 
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transfer the nitrocellulose membrane was washed three times with 1 X TBS-T (Tris-buffered 
saline containing 0.02% Triton X-100). The membrane was blocked in 5% Biorad blocker 
(Biorad #170-6404) in TBS-T for one hour at room temperature, followed by 3x washes with 
TBS-T. In order to probe for Glycoprotein A33 (GPA33) expression, the membrane was 
incubated overnight at 4˚C in polyclonal Rabbit Anti-GPA33 antibody (Sino Biological #11277-
RP02) at 1:10,000 in 5% Biorad blocker in TBS-T. After the primary antibody incubation, the 
membrane was washed three times with TBS-T, before incubation in Goat anti-Rabbit-IgG HRP 
conjugate (Thermo #31460) at 1:5,000 in 5% Biorad blocker in TBS-T for 1 hour at room 
temperature. All washing and antibody incubations were performed on a rotary shaker. After 
washing three times with TBS-T the membrane was sprayed with luminol chemiluminescent 
substrate (Denville Scientific #E2400). After 1 min, excess luminol reagent was removed with a 
Kimwipe. The blot was imaged using a BioRad GelDoc XR imager. Equivalent protein loading 
in lanes was evaluated by reprobing the blot for GAPDH. The same membrane was washed with 
TBS-T and incubated with rabbit anti GAPDH (Rockland #600-401) at 1:1,000 dilution in 
blocking solution overnight at 4˚C. The same secondary antibody and imaging procedure was 
used as above.  
Gold nanoparticle (GNP) construction 
Conjugation of mAb to GNP was performed essential as described by Kumar et al (2008) 
and modified by Althari (2013).  Briefly, the glycosylation site of As33 was oxidized using 
sodium periodate. The presence of aldehydes was confirmed using the Purpald assay. Then, the 
PEG-hydrazine-dithiol linker was added to the oxidized antibody. The hydrazine on the linker 
formed a stable hydrozone linkage with the oxidized As33.  The linker-modified antibody was 
purified through molecular weight cut off column to remove excess linker and periodate. 100 uL 
16 
of the linkered antibody was incubated with 1 mL of 20 nm citrate stabilized gold colloid (Ted 
Pella #15705, manufactured by BBInternational, UK) for 20 minutes at room temperature with 
shaking. Methoxy-PEG-SH was added to the antibody-conjugated nanoparticles at 500 ug/mL. 
The nanoparticles were then spun at 4,000 x g for 30 minutes at 4˚C. The supernatant was 
discarded and the resulting pellet was resuspended in 2% PEG in PBS. The conjugated GNPs 
were resuspended (at 1012 particles/mL) in RPMI without bovine serum but containing 0.2% 
BSA (American Bioanalytical #AB0440). GNP concentration were calculated based on the 
published (Ted Pella & BBI) extinction coefficient data, which for these 20nm GNP is 7 x 1011 
particles/mL colloid suspension with an “absorption” at 520 nm of 1.0 OD. The gold 
nanoparticles constructs were stored in the dark at 4˚C. 
 






Cells, that had been grown in CO2 Independent Conditions for three passages, were 
seeded at 10,000 cells/well in duplicate 96 well plates (irradiated and non-irradiated). After 24 
hours of growth in CO2 Independent media in a 37˚C incubator with 0% CO2, the media was 
replaced with CO2 Independent media mixed with the appropriate treatment. Each condition was 
done in triplicate. The treatments are summarized in Table 1. Untreated cells were merely 
supplemented with fresh CO2 Independent media. The treatments are as follows, 100 nM and 
1µM of sodium mercaptododecaborate >99.5% enriched (Katchem, Czech Republic) with 10B 
(BSH), 107/mL and 108/mL GNP conjugated to mAb As33 (GNP-As33),  107/mL and 108/mL of 
GNP conjugated to mAb As33 and loaded with BSH (GNP-As33-BSH) (Table 1). The samples 
were incubated in a portable humidified 37˚C incubator for 3 hours while transferred to MIT 
Nuclear Reactor Lab (NRL).  
In order to expose the cells to low thermal energy neutrons, the samples were irradiated 
for 2 min at a beam power of 5 MW.  Thermal neutron and boron doses were determined for us 
by Kent Riley using activation of gold foils placed in wells plate (containing complete RPMI 
medium) spaced around the plate as described in Althari (2013). Thirty minutes after the 
irradiation, the media was removed and replaced with fresh CO2 Independent Media with 10% of 
the WST-8 reagent. This delay was due to safety protocols that involved determining the 
remaining radiation of the samples before it could leave the reactor core. Following a 3 hour 
incubation in a portable humidified incubator at 37˚C, the plate was read at 490 instead of 450 
due to available filters in the BioTek Elx800 plate reader located at NRL. A second reading was 
obtained 18.5 hours later. Cell viability was determined as a percentage of the untreated cells. 
Blank-corrected absorbance values of the treatment conditions were divided by the blank-
18 

















































Cell Growth in CO2 Independent Environment 
In order to carry out the irradiation experiments, the cells must be transported to the MIT 
Nuclear Reactor Lab. This involves the cells being transported and maintained in a non-CO2 
regulated humidified portable incubator at 37˚C. Traditional cell culture medium (e.g. RPMI) is 
buffered by sodium bicarbonate, which relies on high CO2 for its buffering capacity. Growing 
cells in traditional cell culture media without regulated CO2 results in a pH imbalance and cell 
death. In order to carry out experiments outside of a CO2 regulated environment, the cells were 
adapted to CO2 Independent Medium (GIBCO) buffered with sodium phosphate and β-
glycerophosphate and capable of maintaining long-term pH stability under atmospheric CO2 
conditions. 
 Significant changes in cellular function and viability could prevent adequate results from 
being obtained by future experiments. Since the cells are normally cultured in 5% CO2 in RPMI 
media, we evaluated the change in cell morphology and cell viability when the cells were 
switched to CO2 Independent Conditions (0% CO2, CO2 Independent Media).  
As shown in Figure 7, cells adapted to the CO2 Independent media did not have 
significantly altered cell morphology from cells grown in normal conditions. To further 
characterize cell growth in CO2 independent conditions, the cell viability of cells grown in CO2 
independent conditions relative to normal conditions was determined using the Cell Proliferation 
Kit 8 (CCK-8, Dojindo) (Fig 8). CCK-8 uses an active reagent WST-8 that when reduced by live 
cells changes color. Using the CCK-8 assay, the culture of cells in the CO2 Independent Media 
dramatically improves viability relative to RPMI under 0% CO2 (Fig 8). In fact, cells grown for 
24 h or 48h in RPMI in 0% CO2 resulted in more cytotoxicity than cells grown under normal 
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conditions (RPMI, 5% CO2) when treated with a high concentration (1 mM) of the 
topoisomerase inhibitor cancer drug etoposide (VP-16) (Fig 7). From this experiment it appears 
CAPAN2 is more viable that BxPC3 in CO2 Independent Conditions (Fig 7.) Although since the 
CCK-8 cell viability assay is based on the extracellular reduction of the reagent (WST-8) by 
mitochondrial NADH, it is possible that CCK-8 could be influenced by changes in cellular 
metabolism as well as cell number and viability.  The fact that WST-8 is extracellular makes it 
less cytotoxic to cells and allows for culture in the reagent for long incubation periods. 
Figure 7: Cell morphology in normal and CO2 independent conditions. Cells were 
grown in either normal conditions (RPMI, 5% CO2) or CO2 independent conditions (CO2 
Independent Media, Gibco and 0% CO2). Cells were seeded at an equal number for normal and 













Figure 8: Cell viability in a non-CO2 atmosphere. Prior to the experiment both BxPC3 (A) 
CAPAN2 (B) cells were directly adapted to CO2 Independent Media, by culture in the CO2 
independent media for three passages. Cells were grown in 96 well plates (5,000 cells/well) in a 
humidified but non-CO2 atmosphere at 37˚C, in either CO2 Independent Media or RMPI Media 
(sodium bicarbonate buffer). Treatments were done in triplicate. After 24 and 48 hours in a non-
CO2 atmosphere, the viability was measured with the CCK-8 kit (Dojindo). Viability is 
represented as the percent of the control (cells grown under normal conditions; RPMI, 5%CO2, 
and 37˚C).  Etoposide (VP-16; 1 mM) was used as a control for cell death. Cells treated with VP-







































































CO2 Independent Conditions Do Not Alter A33 Expression 
 The main purpose of this experiment is to assess the targeted therapy through a 
monoclonal antibody designated As33, which is directed against A33. Under regular growth 
conditions BxPC3 cells do not express detectible levels of A33 while CAPAN2 cells express 
copious amounts of the antigen A33. The biggest concern, for these experiments, is that altering 
the growth conditions cells could change the expression of A33. As shown in Figure 9, A33 
expression might be slightly decreased in CO2 independent conditions however the overall 
pattern remains the same; BxPC3 cells lack detectible A33 expression, while CAPAN2 cells 




Figure 9: A33 expression in BxPC3 and CAPAN2 under normal and CO2 independent 
conditions. A33 expression was evaluated by a western blot. The upper arrow indicates 
membrane A33 and the lower arrow indicates the cytosolic form of A33. GAPDH was run as a 
loading control. 1) BxPC3 grown under 5% CO2 in sodium bicarbonate buffered media (RMPI, 
Sigma) 2) BxPC3 grown under 0% CO2 in CO2 Independent media (GIBCO). 3) CAPAN2 
grown under 5% CO2 in sodium bicarbonate buffered media 4) CAPAN2 grown under 0% CO2 
in CO2 Independent media.    
 
 





 In order to test the toxicity of BNCT delivery through monoclonal antibody conjugated 
gold nanoparticles (GNP), pancreatic adenocarcinoma cells expressing A33, CAPAN2, and not 
expressing A33, BxPC3, were treated with gold nanoparticles conjugated to the monoclonal 
antibody As33 directed against the glycoprotein A33 and loaded with boron-10 (GNP-AsA33-
BSH). After treatment the cells were exposed to low thermal energy neutrons, and the 
cytotoxicity was observed at two time points using the CCK-8 assay. The triplicates for each 
treatment were highly variable and clear outliers were discarded (see Appendix for raw data and 
neutron dose distribution). This experiment must be repeated with less variability for the 
following observations to be validated. GNP-As33-BSH did not have much of an effect on non-
irradiated cells, but resulted in a large decrease in cell viability after irradiation for both GNP 
concentrations of 107/mL and 108/mL (Fig 10). There appeared to be no selectivity of GNP-
As33-BSH due to A33 targeting because BxPC3 and CAPAN2 had very similar responses to 
GNP-As33-BSH (Fig 10).  
The cells were also treated with GNP just conjugated to mAb As33 alone (GNP-AsA33) 
to determine if the BSH conferred additional cytotoxicity after irradiation. In irradiated BxPC3 
cells, GNP-As33 reduced cell viability by approximately 60% and 80%, for GNP treatments of 
107/mL and 108/mL respectively. Irradiated CAPAN2 cells pretreated with 107/mL GNP-As33 
had approximately an 85% decrease in cell viability. However when irradiated CAPAN2 cells 
were pretreated with 108/mL GNP-As33 there was not much of decrease in cell viability. This 
inconsistence makes it hard to interpret the effect of GNP-As33. Additional experiments are 
needed to determine if this is experimental error or not. The cells were also treated with BSH 
alone to determine the effect of BSH alone before and after irradiation. This produced an 
24 
unexpected result that BSH reduced viability more in the non-irradiated cells than cells that had 
been exposed to low thermal energy neutrons (Fig 10).  
The second reading, the following morning after irradiation, produced similar results 
except there appeared to be cell recovery in most irradiation treatments (Fig 10). Importantly the 
least recovery was seen in the GNP-As33-BSH irradiated cells (Fig 10). It appears that 
irradiation increases the toxicity of both GNP-As33-BSH and GNP-As33. From this experiment 
there does not seem to be a detectible level of selectivity based on A33 expression. However 






 Figure 10: Cytotoxicity of Pancreatic adenocarcinoma cells, BxPC3 and CAPAN2, exposed 
to BSH and gold nanoparticle constructs after exposure to low thermal energy neutrons. The 
cells were grown in CO2 independent conditions for 3 passages. Both BxPC3 and CAPAN2 were 
seeded at 10,000 cells per well. After 24 hours the cells were treated with the following conditions 
100 nM and 1µM of BSM, 107 particles/mL and 108 particles/mL GNP conjugated to mAb As33 
(GNP-As33), 107 particles/mL and 108 particles/mL of GNP conjugated to mAb As33 and loaded 
with BSH (GNP-As33-BSH).  After 3 hours incubation, the cells were exposed to low thermal 
energy neutrons (2 min at a beam power of 5MW). Thirty minutes after irradiation, 10% WST 
reagent in CO2 independent media was added. Read 1 is 3.5 hours after irradiation and read 2 is 22 
hours after irradiation. Bars represent averages of 2 or 3 values (See Appendix A Table 1 and 


























































































































































































































A. Repetition and reducing variability in BNCT irradiation experiments 
A preliminary irradiation experiment was performed to examine cytotoxicity of 
nanoparticles in cells (Fig 10). There was a high level of variability within the replicate samples 
(Appendix, Table 1 and Table 2) that could be attributed to uneven distribution of the radiation 
across the wells of the plate. Following irradiation of the cells, the level of neutron flux was 
determined through analysis of gold foils by our collaborator Kent Riley. It was determined that 
the wells on the corners of the plate received a lower dose of thermal energy neutrons compared 
to wells closer to the center of the plate (Appendix, Fig 1). This could be corrected for by 
seeding the cells to a more limited area in the center of the plate.  
It is also possible that despite allowing cells to adhere to the wells for twenty-four hours 
prior to the experiment, the use of RPMI without serum and supplemented with 0.2% BSA was 
disruptive to maintenance of maximal adhesion. Cells that did not adhere fully to the plate could 
have been disrupted during cell transport and handling. Future experiments should be performed 
to evaluate cell adhesion under these conditions to minimize well-to-well variability. Given the 
observed difference in cell growth between CAPAN2 and BxPC3, it will be important to 
determine specific cell numbers per well at the time of GNP treatment to equalize the GNP/cell 
dose of exposure. 
B. Determining Targeting Specificity and Internalization of Nanoparticle Constructs 
 No significant selectivity correlated to A33 expression was observed with either the 
GNP-As33 and GNP-As33-BSH treatments prior to or following irradiation of the cells (Fig 9).  
This result was disappointing since prior work by our group (Pollack 2013) has demonstrated 
specific targeting of As33-conjugated GNP to CAPAN2 xenografts grown on the chick CAM in 
27 
vivo model.  Future experiments will use bare GNP as a control to determine corresponding 
cytotoxicity (if any) in both BxPC3 and CAPAN2 cell lines. The observed lack of selectivity 
could be the result of nonspecific internalization or association with the membrane of A33 
negative BxPC3 cells. Additionally, this lack of specificity could be caused by inadequate 
removal of media containing the functionalized GNPs, which might have had a cytotoxic effect 
on nearby cells after irradiation. This eventuality is of concern especially since there was an 
apparent BNCT effect in samples in this study where BSH was dissolved in the culture media 
(Fig 10).  Future experiments will look at internalization of GNP-As33-BSH in both CAPAN2 
and BxPC3 to look for A33 receptor-mediated endocytosis and compare results when the media 
is changed prior to irradiation so that the only nanoparticles present in the system are the GNP 
constructs internalized by the cells.   
C. Increasing boron concentration on GNP through pEK peptide. 
 The apparent lack of BNCT-effect could also be due to suboptimal concentrations of 10B 
being taken up by cells on GNPs.  The method of directly adding BSH onto the GNP used in this 
study likely limit the amount of BSH that can be loaded. In order for BNCT to be effective, high 
amounts of 10B need to be localized to the tumor cells (Barth et al 2005). Conjugating a small 
peptide loaded with BSH would allow for higher concentrations of boron per nanoparticle than 
the direct conjugation of BSH to GNP. This in turn could potentially increase therapeutic levels 
of 10B. Nowinski et al. have developed a novel peptide, poly-EK (pEK) which is ideal for boron 
loading due to its high lysine content, hydrophilicity, and lack of bulky aromatic residues 
(Nowinski et al., 2014). pEK has the sequence of EKEKEKEKE-PPPPC where  the C-terminal 
cysteine residue facilitates a thiol-gold interaction to directly connect pEK to GNP through a 
dative linkage. The homo-proline stretch adds rigidity to allow for tighter packing enabling a 
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larger quantity of peptides to assemble on GNP.  Additionally pEK is advantageous for boron 
loading because boron can be attached to the lysines, through the hetero-functional sulfo-MBS 
cross-linker (Fig 11). The NHS-ester group of sulfo-MBS reacts with primary amine groups, 
found on the lysines of pEK, and forms an amide bond. On the other end of sulfo-MBS is a 
maleimide group. The maleimide reacts with the thiol on BSH, creating a very stable thioether 
bond.  
Furthermore, pEK was shown to perform similar in vivo functions as PEG without the 
biological toxicity; namely forming “stealth, non-fouling” GNP with high stability and low 
agglomeration characteristics in serum (Nowinski et al., 2014).  Using boronated pEK would 
prevent the need to backfill the nanoparticles with PEG.  PEG has been shown to cause liver 
toxicity in mice (Rudmann et al., 2013). Switching to boronated pEK would serve dual functions 





Figure 11: Boronation of lysines through sulfo-MBS. The amine of the lysine attacks the ester 
bond forming an amide bond. Then the malimide reacts with the thoil on BSH forming a stable 









A. Future targets: Pancreatic cancer stem cells  
Recent work has identified stem cell-like pancreatic cells responsible for the highly 
metastatic nature of pancreatic cancer. In 2007 a study identified a population of pancreatic cells 
expressing the cell surface markers CD44, CD24, and ESA.  When a small number of these cells 
were injected into nude mice, they all formed heterogeneous tumors, a common characteristic of 
cancer stem cells (CSC) (Li et al., 2007).   
Another group found that CD133+ cells isolated from pancreatic cancer patients formed 
tumors in nude mice at a much higher rate than CD133- cells (Hermann et al., 2007).   In 
addition Hermann et al. showed that gemcitabine, commonly used to treat pancreatic cancer, 
significantly enriched the CD133+ positive cells in a pancreatic cancer cell line. Additionally this 
study highlighted that pancreatic CSC were heterogeneous. Hermann et al. further identified a 
subpopulation, CD133+CXCR4+ that were highly invasive. They showed that treatment with 
anti-CXCR4 monoclonal antibody (mAb CXCR4) decreased in vitro cell migration of a 
pancreatic adenocarcinoma cell line (L3.6 pl). 
Together these two studies highlight the complexity and importance of pancreatic CSC in 
pancreatic cancer metastasis and further indicate the inefficiency of chemotherapy to target these 
CSC. The question still remains whether there are two distinct pancreatic cancer stem cell 
populations, or if the makeup of CSC varies between patients. Despite the complexities these 
studies also provide some hope, because they point to surface markers that could hopefully be 
exploited for targeting moieities in the future to directly kill pancreatic CSC implicated in 
metastasis. The inhibitory effect of mAb CXCR4 on in vitro pancreatic cancer migration is 
particularly promising.  
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Recent work on cancer stem cells indicates that it may be time to rethink traditional 
chemotherapy methods, which might actually enrich for CSC in the tumor cell population. 
BNCT could provide an alternative to traditional chemotherapy and radiation.  In fact BNCT has 
been shown to be effective in arresting and killing glioma cancer stem cells and progenitor cells 
(Sun et al., 2013). As the research narrows in on identifying surface markers for pancreatic 
CSCs, it is tempting to hypothesize that targeting GNP conjugated with boron-10 enriched 
compounds to pancreatic cancer stem cells using surface markers could help improve long term 
outcome of patients treated with BNCT.  
Conclusions 
 Medical nanotechnology holds a lot of promise for the therapy of cancer and other severe 
conditions. At present, there is an unmet medical need for targeted cancer therapeutics. More 
broad-spectrum approaches could prove harmful to the patient and come with a variety of severe 
side effects. However, with a more targeted approach, the therapeutic could be delivered only to 
cells overexpressing a particular cell surface receptor through the use of highly specific 
monoclonal antibodies. Particularly in the case of pancreatic adenocarcinoma, there are very few 
options, surgical or otherwise, that can be used to treat the cancer, leading to an incredibly low 
survival rate. However, the use of gold nanoparticles allows for a high surface-to-volume ratio, 
which allows for the attachement of both therapeutic and targeting moieities. Additionally, gold 
is highly biocompatible as it is a noble metal and does not oxidize easily, as other metals do. 
Nanotechnology may be able to revive boron neutron capture therapy (BNCT). Using 
monoclonal antibody-conjugated gold nanoparticles as a targeting mechanism for BNCT could 
potentially resolve two main problems with the clinical application of BNCT, high levels of 
boron left circulating in the blood and low levels in target tissues. Targeting of this therapy using 
32 
mAbs could potentially decrease levels of 10B in other tissues at the time of irradiation, while 
concentrating potentially several hundred BSH molecules on a single GNP could potentially help 
increase the therapeutic load. This thesis developed an experimental set up to evaluate the 
cytotoxicity of gold nanoparticles following irradiation of 10B-loaded and monoclonal antibody 
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Table 1: Raw Data From Irradiation Experiment Initial Reading (3.5 h after irradiation). 
Highlighted values were omitted from analysis. 
 
Table 2: Raw Data From Irradiation Experiment Second Reading (22.5 h after irradiation) 





Media 0.325 0.284 0.378 0.697 0.278 0.714
BSH 1uM 0.487 0.142 0.119 0.169 0.087 0.103
BSH 100 nM 0.108 0.349 0.18 0.088 0.129 0.149
GNP-A33 10,000/cell 0.558 0.388 0.424 0.097 0.401 0.783
GNP-A33 100,000/cell 0.226 0.419 0.214 0.161 0.542 0.859
GNP-A33-BSH 10,000/cell 0.423 0.315 0.356 0.755 0.43 0.665
GNP-A330-BSH 100,000/cell 0.307 0.291 0.388 0.724 0.835 0.655
Blank 0.089 0.1 0.105
Media 0.791 0.644 0.763 1.012 0.653 1.042
BSH 1uM 0.435 0.43 0.624 0.363 0.899 0.091
BSH 100 nM 0.089 0.578 0.49 0.435 0.497 0.559
GNP-A33 10,000/cell 0.46 0.231 0.831 0.226 0.1 0.147
GNP-A33 100,000/cell 0.18 0.411 0.09 0.307 0.549 0.877
GNP-A33-BSH 10,000/cell 0.115 0.114 0.16 0.143 0.091 0.121
GNP-A330-BSH 100,000/cell 0.13 0.105 0.098 0.103 0.139 0.683





Media 0.995 0.938 1.16 1.733 0.774 1.897
BSH 1uM 1.48 0.378 0.246 0.505 0.104 0.182
BSH 100 nM 0.22 1.098 0.559 0.111 0.339 0.41
GNP-A33 10,000/cell 1.759 1.182 1.259 0.14 1.258 2.195
GNP-A33 100,000/cell 0.76 1.258 0.658 0.446 2.207 1.637
GNP-A33-BSH 10,000/cell 1.251 0.956 1.118 2.15 1.334 1.844
GNP-A330-BSH 100,000/cell 1.202 0.886 1.179 2.177 2.133 1.881
Blank 0.114 0.164 0.183
Media 2.157 2.051 2.174 2.237 1.735 2.222
BSH 1uM 1.397 1.312 2.032 1.041 2.225 0.11
BSH 100 nM 0.106 1.866 1.387 1.699 1.425 1.844
GNP-A33 10,000/cell 2.032 1.451 1.387 1.088 0.193 0.397
GNP-A33 100,000/cell 0.5567 1.299 0.105 1.088 2.238 1.889
GNP-A33-BSH 10,000/cell 0.222 0.233 0.468 0.447 0.166 0.289
GNP-A330-BSH 100,000/cell 0.274 0.159 0.119 0.192 0.391 2.16







Figure 1: Thermal Flux (109 neutrons cm-2 s-1) is greater in wells in the center than on the 
corners of the 96 well plate. (Data calculated courtesy of Kent Riley). Wells D7 and B4 contain 
gold foil covered with media, while wells E6 and G10 just contain gold foils. 
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